Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial Trastuzumab for HER2+ Breast Cancer Brain Metastases
NCT02571530Phase 1Terminated
- Sponsor
- Northwell Health
- Start
- Aug 2015
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by Northwell Health. Primary endpoints: Maximum Tolerated Dose at 30 days and Adverse events and dose-limiting toxicities at 30 days. Started Aug 2015; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02571530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571530.